EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2026

Publisher Name :
Date: 01-Nov-2017
No. of pages: 35

EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2026

Summary

Multiple sclerosis (MS) is an autoimmune disease affecting principally the central nervous system that causes nerve sheath demyelination followed by axon damage and paralysis. MS symptoms include muscle weakness, weak reflexes, tremor, muscle spasm, prolonged double vision, slurred speech, and balance problems. It can occur at any age, but commonly affects people of ages 15-60 years. Women are about twice as likely as men to develop this disease (Mayo Clinic, 2016). MS symptoms may occur and disappear completely, while the permanent neurological problems occur when the disease advances.

Our epidemiologists forecast that the diagnosed prevalent cases of MS in the 7MM will grow by an Annual Growth Rate (AGR) of almost 0.8% per year over the next 10 years, from around 1 million cases in 2016 to around 1.1 million cases in 2026. Of the 7MM, the US had the highest number of diagnosed prevalent cases with around 0.4 million cases in 2016, while Japan had the lowest number of diagnosed prevalent cases with almost 20,000 cases in 2016. In 2016, the US accounted for around 40% of all the diagnosed prevalent cases of MS, while Japan accounted for only about 2% of diagnosed prevalent cases of MS in the 7MM.

Our epidemiologists forecast that the diagnosed incident cases of MS in the 7MM will grow by an AGR of around 0.3% per year over the next 10 years, from around 49,000 cases in 2016 to just over 50,000 cases in 2026. Additionally, the US will have the highest AGR of almost 0.8%, while Italy will have the lowest at negative rate of around 0.5%. From the 7MM, the US had the highest number of diagnosed incident cases of MS with over 20,000 cases in 2016, while Japan had the lowest number of diagnosed incident cases of MS with nearly 1,000 cases in 2016. In 2016, the US accounted for over 42% of all the MS cases, while Japan accounted for only about 2% of diagnosed incident cases of MS in the 7MM.

The report "EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2026", provides an overview of the risk factors, comorbidities, and the global and historical trends for MS in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiological forecast for the diagnosed prevalent and diagnosed incident cases of MS, segmented by sex and by age (for all ages) in these markets. The diagnosed prevalent cases are further segmented by types of MS (relapsing-remitting [RRMS], primary progressive [PPMS], and secondary progressive [SPMS]) in the 7MM.

Scope

- The Multiple sclerosis (MS) EpiCast Report provides an overview of the risk factors and global trends for MS in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiological forecast for the diagnosed prevalent and diagnosed incident cases of MS, segmented by sex and by age (for all ages) in these markets. The diagnosed prevalent cases are further segmented by types of MS (relapsing-remitting [RRMS], primary progressive [PPMS], and secondary progressive [SPMS]) in the 7MM.

- The MS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The MS EpiCast report will allow you to -

- Develop business strategies by understanding the trends shaping and driving the global MS market.

- Quantify patient populations in the global MS market to improve product design, pricing, and launch plans.

- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for MS therapeutics in each of the markets covered.

- Understand magnitude of MS population by disease type.

EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2026

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Multiple Sclerosis Executive Summary 4
2.1 Related Reports 6
2.2 Upcoming Reports 6
3 Epidemiology 7
3.1 Disease Background 7
3.2 Risk Factors and Comorbidities 7
3.3 Global and Historical Trends 8
3.4 Forecast Methodology 10
3.4.1 Sources 10
3.4.2 Forecast Assumptions and Methods 13
3.4.3 Diagnosed Prevalent Cases of MS 14
3.4.4 Diagnosed Prevalent Cases of MS by Types 17
3.4.5 Diagnosed Incident Cases of MS 19
3.5 Epidemiological Forecast for MS (2016-2026) 21
3.5.1 Diagnosed Prevalent Cases of MS 21
3.5.2 Age-Specific Diagnosed Prevalent Cases of MS 22
3.5.3 Sex-Specific Diagnosed Prevalent Cases of MS 22
3.5.4 Diagnosed Prevalent Cases of MS by Types 23
3.5.5 Diagnosed Incident Cases of MS 24
3.5.6 Age-Specific Diagnosed Incident Cases of MS 25
3.5.7 Sex-Specific Diagnosed Incident Cases of MS 26
3.6 Discussion 27
3.6.1 Epidemiological Forecast Insight 27
3.6.2 Limitation of Analysis 28
3.6.3 Strengths of Analysis 29
4 Appendix 30
4.1 Bibliography 30
4.2 About the Authors 32
4.2.1 Epidemiologist 32
4.2.2 Reviewers 33
4.2.3 Global Director of Therapy Analysis and Epidemiology 33
4.2.4 Global Head and EVP of Healthcare Operations and Strategy 34
4.3 About GlobalData 35
4.4 Contact Us 35
4.5 Disclaimer 35

1.1 List of Tables
Table 1: Risk Factors and Comorbidities for MS 8
Table 2: 7MM, Diagnosed Prevalent Cases of MS, Both Sexes, All Ages, Selected Years 2016-2026 21
Table 3: 7MM, Diagnosed Incident Cases of MS, Both Sexes, All Ages, Selected Years 2016-2026 25

1.2 List of Figures
Figure 1: 7MM, Diagnosed Prevalent Cases of MS, Both Sexes, All Ages,2016 and 2026 5
Figure 2: 7MM, Diagnosed Incident Cases of MS, Both Sexes, All Ages, 2016 and 2026 6
Figure 3: 7MM, Age-Standardized Diagnosed Prevalence of MS (%), Both Sexes, All Ages, 2016 9
Figure 4: 7MM, Age-Standardized Diagnosed Incidence of MS (Cases per 100,000 Population), Both Sexes, All Ages, 2016 10
Figure 5: 7MM, Sources Used and Not Used, Diagnosed Prevalent Cases of MS 11
Figure 6: 7MM, Sources Used and Not Used, Diagnosed Incident Cases of MS 12
Figure 7: 7MM, Sources Used and Not Used for the Diagnosed Prevalent Cases of MS by Types 13
Figure 8: 7MM, Age-Specific Diagnosed Prevalent Cases of MS, Both Sexes, All Ages, 2016 22
Figure 9: 7MM, Sex-Specific Diagnosed Prevalent Cases of MS, Both Sexes, All Ages, 2016 23
Figure 10: 7MM, Diagnosed Prevalent Cases of MS by Types, Both Sexes, All Ages, 2016 24
Figure 11: 7MM, Age-Specific Diagnosed Incident Cases of MS, Both Sexes, All Ages, 2016 26
Figure 12: 7MM, Sex-Specific Diagnosed Incident Cases of MS, Both Sexes, All Ages, 2016 27
  • Multiple Sclerosis - Pipeline Review, H2 2017
    Published: 21-Dec-2017        Price: US 2500 Onwards        Pages: 780
    Multiple Sclerosis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Sclerosis - Pipeline Review, H2 2017, provides an overview of the Multiple Sclerosis (Central Nervous System) pipeline landscape. Multiple sclerosis (MS) is a potentially debilitating disease in which body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes ......
  • Multiple Sclerosis -Epidemiology Forecast to 2025
    Published: 01-Nov-2017        Price: US 2750 Onwards        Pages: 40
    DelveInsight "Multiple Sclerosis - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Multiple Sclerosis in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Multiple Sclerosis prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated w......
  • Multiple Sclerosis - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 01-Nov-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Multiple Sclerosis - Market Insights, Epidemiology and Market Forecast - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Multiple Sclerosis - Market Insights, Epidemiology and Market Forecast for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patt......
  • Global Multiple Sclerosis Drugs Market Professional Survey Report 2017
    Published: 01-Nov-2017        Price: US 3500 Onwards        Pages: 105
    This report studies Multiple Sclerosis Drugs in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Biogen - Teva Pharmaceutical - Merck KGaA - Novartis ......
  • Relapsing Multiple Sclerosis (RMS) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Nov-2017        Price: US 1500 Onwards        Pages: 40
    DelveInsight's, Relapsing Multiple Sclerosis (RMS) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" report provides comprehensive insights about marketed and Phase III products for the Relapsing Multiple Sclerosis (RMS). The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. It also provides a comprehensive understanding of the emerging Phase III therapies......
  • Secondary Progressive Multiple Sclerosis (SPMS) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Nov-2017        Price: US 2000 Onwards        Pages: 60
    DelveInsight's, Secondary Progressive Multiple Sclerosis (SPMS) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" report provides comprehensive insights about marketed and Phase III products for the Secondary Progressive Multiple Sclerosis (SPMS). The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. It also provides a comprehensive understanding of the em......
  • Global Multiple Sclerosis Partnering 2010 to 2017
    Published: 01-Nov-2017        Price: US 1495 Onwards        Pages: 150
    "Delivery of this report will take 1-3 days after purchase." The Global Multiple Sclerosis Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. • Trends in partnering deals • Top deals by value • Deals listed by company A-Z, industry sector, stage of development, technology type The report provides ......
  • Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Insight, 2017
    Published: 01-Nov-2017        Price: US 1250 Onwards        Pages: 50
    DelveInsight's, "Primary Progressive Multiple Sclerosis (PPMS)-Pipeline Insights, 2017", report provides comprehensive insights of the ongoing therapeutic research and development across Primary Progressive Multiple Sclerosis (PPMS). The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Primary Progressive Multiple Sclerosis (PPMS) by development stage, therapy ty......
  • Relapsing Multiple Sclerosis (RMS) - Pipeline Insight, 2017
    Published: 01-Nov-2017        Price: US 1250 Onwards        Pages: 50
    DelveInsight's, "Relapsing Multiple Sclerosis (RMS)-Pipeline Insights, 2017", report provides comprehensive insights of the ongoing therapeutic research and development across Relapsing Multiple Sclerosis (RMS). The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Relapsing Multiple Sclerosis (RMS) by development stage, therapy type, route of administration and m......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs